Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021

Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021

  • July 2021 •
  • 60 pages •
  • Report ID: 6124406 •
  • Format: PDF
“Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Acute Bacterial Skin and Skin Structure Infections Understanding

Acute Bacterial Skin and Skin Structure Infections: Overview
Acute Bacterial Skin and Skin Structure Infection is a bacterial infection of the skin and associated tissues. The FDA defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ?38°C (100.4°F). Some of the most common bacterial pathogens that cause Acute Bacterial Skin and Skin Structure Infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S.aureus. Less common causes include other Streptococcus species, Enterococcus faecalis, or Gram Negative bacteria.

"Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Bacterial Skin and Skin Structure Infections pipeline landscape is provided which includes the disease overview and Acute Bacterial Skin and Skin Structure Infections treatment guidelines. The assessment part of the report embraces, in depth Acute Bacterial Skin and Skin Structure Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Bacterial Skin and Skin Structure Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Bacterial Skin and Skin Structure Infections R&D. The therapies under development are focused on novel approaches to treat/improve Acute Bacterial Skin and Skin Structure Infections.

Acute Bacterial Skin and Skin Structure Infections Emerging Drugs Chapters
This segment of the Acute Bacterial Skin and Skin Structure Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Bacterial Skin and Skin Structure Infections Emerging Drugs
• Zevtera: Basilea Pharmaceutica
Zevtera (Ceftobiprole medocaril), the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. The drug is approved and marketed as Zevtera® and Mabelio® in a number of countries in Europe and beyond. Basilea has entered into license and distribution agreements for the brand in Europe, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) regions. The drug is currently in Phase III stage of clinical trial evaluation to treat Acute Bacterial Skin and Skin Structure Infections.

• Contezolid acefosamil: MicuRx Pharmaceuticals
Contezolid is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), while offering physicians and patients a new therapeutic option than currently available oxazolidinone agents. The development of contezolid in China has been designated as a “Significant New Drugs Development Special Project”, and contezolid has also been granted QIDP designation and Fast Track status by the US FDA.
Further product details are provided in the report……..

Acute Bacterial Skin and Skin Structure Infections: Therapeutic Assessment
This segment of the report provides insights about the different Acute Bacterial Skin and Skin Structure Infections drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Acute Bacterial Skin and Skin Structure Infections
There are approx. 15+ key companies which are developing the therapies for Acute Bacterial Skin and Skin Structure Infections. The companies which have their Acute Bacterial Skin and Skin Structure Infections drug candidates in the most advanced stage, i.e. phase III include, Basilea Pharmaceutica.

• Phases
This report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Acute Bacterial Skin and Skin Structure Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intradermal
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Bacterial Skin and Skin Structure Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Bacterial Skin and Skin Structure Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Bacterial Skin and Skin Structure Infections drugs.

Acute Bacterial Skin and Skin Structure Infections Report Insights
• Acute Bacterial Skin and Skin Structure Infections Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Bacterial Skin and Skin Structure Infections Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Acute Bacterial Skin and Skin Structure Infections drugs?
• How many Acute Bacterial Skin and Skin Structure Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Bacterial Skin and Skin Structure Infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Bacterial Skin and Skin Structure Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Bacterial Skin and Skin Structure Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Basilea Pharmaceutica
• MicuRx Pharmaceuticals
• TenNor Therapeutics Limited
• GlaxoSmithKline
• Debiopharm Group
• Innovation Pharmaceuticals, Inc.
• Botanix pharmaceuticals
• Taxis Pharmaceuticals

Key Products
• Zevtera
• Contezolid acefosamil
• TNP-2092
• GSK2140944
• Debio 1452
• Brilacidin
• TXA709